Abstract |
The treatment of patients with hypernephroma with xenogeneic immune RNA was discussed. The toxicity from xenogeneic immune RNA therapy was minimal in patients receiving simple doses from 4 to 64 mg intracutaneously and with cumulative doses of 450 mg during a 30-month period.
|
Authors | J B deKernion, K P Ramming |
Journal | National Cancer Institute monograph
(Natl Cancer Inst Monogr)
Issue 49
Pg. 347-9
(Dec 1978)
ISSN: 0083-1921 [Print] United States |
PMID | 748792
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adenocarcinoma
(drug therapy, immunology)
- Humans
- Immunity
- Kidney Neoplasms
(drug therapy, immunology)
- RNA
(immunology, therapeutic use, toxicity)
|